Results 41 to 50 of about 11,284,409 (311)
In silico and in vitro exploration of a tyrosinase for biocatalytic production of catechols
FEBS Open Bio, EarlyView.Tyrosinase from Ralstonia pseudosolanacearum is a promising biocatalyst for producing valuable catechols from monophenol substrates. This tyrosinase is uniquely suited to this due to its high monophenolase : diphenolase ratio. We combined in silico docking and in vivo kinetic characterisation of this tyrosinase with 11 industrially relevant monophenols,
James Britton +6 more
wiley +1 more source
Frontiers in Animal Science, 2023 Dopamine has multiple physiological functions including feed intake control in which it can act as an anorectic or orexigenic agent. This study had the objective to evaluate intra-abomasal administration of L-DOPA (levodopa; L-3,4-dihydroxyphenylalanine)
Eriton E. L. Valente +5 more
doaj +1 more source
, 2007 Electropolymerized film of 3,3′,3″,3‴-tetraaminophthalocyanatonickel(II) (p-NiIITAPc) on glassy carbon (GC) electrode was used for the selective and stable determination of 3,4-dihydroxy-l-phenylalanine (l-dopa) in acetate buffer (pH 4.0) solution.
Abraham John, S., Arumugam , Sivanesan
core +1 more source
CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao +7 more
wiley +1 more source
Neurobiology of Disease, 2013 The serotonin system has recently emerged as an important player in the appearance of l-DOPA-induced dyskinesia (LID) in experimental models of Parkinson's disease, as it provides an unregulated source of l-DOPA-derived dopamine release in the dopamine ...
Elisabetta Tronci +6 more
doaj +1 more source
Hypotension Caused by L-Dopa [PDF]
BMJ, 1970 In 20 patients with idiopathic Parkinsonism maximum tolerated doses of L-dopa were found to induce a mean reduction in blood pressure (erect systolic) of 19·3 mm.Hg, without any significant change in pulse rate. This hypotension may be due to dopamine, acting on adrenergic nerve endings or on the central nervous system itself.
D B, Calne +3 more
openaire +2 more sources
Brazilian Journal of Cardiovascular Surgery, 2004 OBJETIVO: Avaliar os efeitos na função ventricular esquerda do uso precoce e tardio de dopamina, em modelo experimental de coração isolado. MÉTODO: Foram utilizados 60 coelhos em modelo de coração isolado mantido por animal suporte.
Ademar R. Souza +4 more
doaj +1 more source
Advanced Functional Materials, EarlyView.We propose a suture‐complementary approach that integrates optical skin clearing with a strain‐programmable luminescent adhesive patch. Hyaluronic acid promotes transdermal delivery of tartrazine to improve optical clearing and stabilizes its interaction with a photosensitizer. Optical clearing increases the penetration depth of visible light into skin,
Seong‐Jong Kim +6 more
wiley +1 more source
l-3,4-Dihydroxyphenylalanine induces ptosis through a GPR143-independent mechanism in mice
Journal of Pharmacological Sciences, 2016 Through its conversion to dopamine by aromatic l-amino acid decarboxylase (AADC), l-3,4-dihydroxyphenylalanine (l-DOPA) replenishes depleted brain dopamine in Parkinson's disease patients. We recently identified GPR143 as a candidate receptor for l-DOPA.
Suguru Ueda +3 more
doaj +1 more source
L-DOPA for Parkinson's disease-a bittersweet pill [PDF]
, 2019 3,4‐dihydroxy‐L‐phenylalanine (L‐DOPA) is the gold standard treatment for Parkinson's disease. It has earned that title through its highly effective treatment of some of the motor symptoms in the early stages of the disease but it is a far from perfect ...
Lane, Emma L.
core +1 more source